These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 34635674)

  • 1. Neurofilament light chain and α-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes.
    Quadalti C; Calandra-Buonaura G; Baiardi S; Mastrangelo A; Rossi M; Zenesini C; Giannini G; Candelise N; Sambati L; Polischi B; Plazzi G; Capellari S; Cortelli P; Parchi P
    NPJ Parkinsons Dis; 2021 Oct; 7(1):93. PubMed ID: 34635674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined CSF α-SYN RT-QuIC, CSF NFL and midbrain-pons planimetry in degenerative parkinsonisms: From bedside to bench, and back again.
    Compta Y; Painous C; Soto M; Pulido-Salgado M; Fernández M; Camara A; Sánchez V; Bargalló N; Caballol N; Pont-Sunyer C; Buongiorno M; Martin N; Basora M; Tio M; Giraldo DM; Pérez-Soriano A; Zaro I; Muñoz E; Martí MJ; Valldeoriola F
    Parkinsonism Relat Disord; 2022 Jun; 99():33-41. PubMed ID: 35594661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias.
    Baiardi S; Quadalti C; Mammana A; Dellavalle S; Zenesini C; Sambati L; Pantieri R; Polischi B; Romano L; Suffritti M; Bentivenga GM; Randi V; Stanzani-Maserati M; Capellari S; Parchi P
    Alzheimers Res Ther; 2022 Oct; 14(1):153. PubMed ID: 36221099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining salivary α-synuclein seeding activity and miRNA-29a to distinguish Parkinson's disease and multiple system atrophy.
    Luan M; Wei L; Sun Y; Chen J; Jiang Y; Wu W; Li F; Sun W; Zhu L; Wang Z; Deng J
    Parkinsonism Relat Disord; 2024 Aug; 127():107088. PubMed ID: 39111257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies.
    Foulds PG; Yokota O; Thurston A; Davidson Y; Ahmed Z; Holton J; Thompson JC; Akiyama H; Arai T; Hasegawa M; Gerhard A; Allsop D; Mann DM
    Neurobiol Dis; 2012 Jan; 45(1):188-95. PubMed ID: 21856424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders.
    Schulz I; Kruse N; Gera RG; Kremer T; Cedarbaum J; Barbour R; Zago W; Schade S; Otte B; Bartl M; Hutten SJ; Trenkwalder C; Mollenhauer B
    Mov Disord; 2021 Dec; 36(12):2874-2887. PubMed ID: 34363416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma and CSF Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Cross-Sectional and Longitudinal Study.
    Vacchiano V; Mastrangelo A; Zenesini C; Masullo M; Quadalti C; Avoni P; Polischi B; Cherici A; Capellari S; Salvi F; Liguori R; Parchi P
    Front Aging Neurosci; 2021; 13():753242. PubMed ID: 34744694
    [No Abstract]   [Full Text] [Related]  

  • 8. Diagnostic Value of Salivary Real-Time Quaking-Induced Conversion in Parkinson's Disease and Multiple System Atrophy.
    Luan M; Sun Y; Chen J; Jiang Y; Li F; Wei L; Sun W; Ma J; Song L; Liu J; Liu B; Pei Y; Wang Z; Zhu L; Deng J
    Mov Disord; 2022 May; 37(5):1059-1063. PubMed ID: 35278004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient RT-QuIC seeding activity for α-synuclein in olfactory mucosa samples of patients with Parkinson's disease and multiple system atrophy.
    De Luca CMG; Elia AE; Portaleone SM; Cazzaniga FA; Rossi M; Bistaffa E; De Cecco E; Narkiewicz J; Salzano G; Carletta O; Romito L; Devigili G; Soliveri P; Tiraboschi P; Legname G; Tagliavini F; Eleopra R; Giaccone G; Moda F
    Transl Neurodegener; 2019; 8():24. PubMed ID: 31406572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
    Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H
    J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood neurofilament light chain in Parkinson disease and atypical parkinsonisms: A protocol for systematic review and meta-analysis.
    Wang H; Wang W; Shi H; Han L; Pan P
    Medicine (Baltimore); 2020 Oct; 99(40):e21871. PubMed ID: 33019386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Panel of Plasma Biomarkers for Differential Diagnosis of Parkinsonian Syndromes.
    Li Q; Li Z; Han X; Shen X; Wang F; Bai L; Li Z; Zhang R; Wang Y; Zhu X
    Front Neurosci; 2022; 16():805953. PubMed ID: 35250451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder.
    Hansson O; Janelidze S; Hall S; Magdalinou N; Lees AJ; Andreasson U; Norgren N; Linder J; Forsgren L; Constantinescu R; Zetterberg H; Blennow K;
    Neurology; 2017 Mar; 88(10):930-937. PubMed ID: 28179466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic Resonance Imaging and Neurofilament Light in the Differentiation of Parkinsonism.
    Archer DB; Mitchell T; Burciu RG; Yang J; Nigro S; Quattrone A; Quattrone A; Jeromin A; McFarland NR; Okun MS; Vaillancourt DE
    Mov Disord; 2020 Aug; 35(8):1388-1395. PubMed ID: 32357259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders.
    Herbert MK; Aerts MB; Beenes M; Norgren N; Esselink RA; Bloem BR; Kuiperij HB; Verbeek MM
    Front Neurol; 2015; 6():91. PubMed ID: 25999911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies.
    Rossi M; Candelise N; Baiardi S; Capellari S; Giannini G; Orrù CD; Antelmi E; Mammana A; Hughson AG; Calandra-Buonaura G; Ladogana A; Plazzi G; Cortelli P; Caughey B; Parchi P
    Acta Neuropathol; 2020 Jul; 140(1):49-62. PubMed ID: 32342188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative susceptibility mapping and blood neurofilament light chain differentiate between parkinsonian disorders.
    Zhang P; Chen J; Cai T; He C; Li Y; Li X; Chen Z; Wang L; Zhang Y
    Front Aging Neurosci; 2022; 14():909552. PubMed ID: 35992605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson's disease: a meta-analysis.
    Hu X; Yang Y; Gong D
    Neurol Sci; 2017 Mar; 38(3):407-414. PubMed ID: 27896490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated Plasma and Neuroimaging Biomarkers Associated with Motor and Cognition Severity in Parkinson's Disease.
    Chen CH; Lee BC; Lin CH
    J Parkinsons Dis; 2020; 10(1):77-88. PubMed ID: 31868681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.